Combination of Virtual Reality and Standard of Care Versus Standard of Care Alone for Acute Musculoskeletal Pain Management in Geriatric Emergency Department Patients: A Randomized Clinical Trial

The proposed Virtual Reality as an Adjunct to Pain Management for Geriatric Patients in the ED (VRAP-ED) project will take place in the Emergency Medicine Department at Maimonides Medical Center. It seeks to enhance the analgesic practices for geriatric patients with acute painful conditions in the emergency setting. Although virtual reality (VR) has demonstrated effectiveness in reducing pain and anxiety in various clinical settings for juveniles and adults, the analgesic efficacy of VR for geriatric ED patients lacks established data. The project will use a geriatric-focused VR platform.
The project intends to improve pain management for almost 200 geriatric patients by evaluating the effectiveness of virtual reality (VR) in reducing pain and its impact on anxiety & stress reduction. The research project will conduct a randomized clinical trial to investigate the analgesic efficacy and impact on anxiety & stress by using VR as an adjunct to the standard of care (SOC) for pain management in elderly patients presenting to the ED with acute musculoskeletal pain. This will be investigated through a prospective, randomized, non-blinded clinical trial conducted over two years. Eligible patients will be randomly assigned to either the control (SOC) or intervention (SOC+VR) groups. The expected outcomes of this research study will provide insight into the feasibility of using VR in a busy emergency setting for one of the most commonly encountered painful syndromes and to assess the analgesic efficacy as well as the satisfaction of VR application by both patients and ED clinicians.

Start Date18 Nov 2024

Sponsor / Collaborator

Maimonides Medical Center

NCT06040840

/ RecruitingNot Applicable

WALANT Versus Axillary Brachial Plexus Block in Carpal Tunnel Release: a Non-inferiority Randomized Controlled Trial

Carpal tunnel syndrome (CTS) is a common medical condition that remains one of the most frequently reported forms of median nerve compression. Surgical procedure is a treatment option for CTS. For this surgery of the upper extremity, regional anesthesia (RA) is the strategy that should be systematically preferred because it is associated with shorter postanesthetic care and less pain compared to general anesthesia. Multiple approaches to block the brachial plexus are available for the surgery of the upper extremity below the elbow, but the axillary block (BAX) remains the most common approach as it is associated with low side effects.
One of the most significant recent advances in the surgery of the upper extremity has been the emergence of Wide-Awake Local Anesthesia No Tourniquet (WALANT) technique. WALANT is an infiltration technique of a local anesthetic (LA) (lidocaine) and a hemostatic agent (epinephrine) directly into the operative site to induce anesthesia and hemostasis in the area of the surgical procedure to provide conditions suitable for hand surgery without sedation and tourniquet. Given its effectiveness and low side effects, WALANT could be a technique of choice in ambulatory surgery.
The main objective of this non-inferiority, prospective, randomized, open-label, parallel-group controlled trial is to assess the efficacy of WALANT technique compared to BAX in carpal tunnel release (CTR).

Start Date13 May 2024

Sponsor / Collaborator

Clinique Ambroise Paré SA

NCT06057675

/ RecruitingPhase 2IIT

Subcutaneous Tranexamic Acid in Nasal Mohs Local Flap Reconstruction: Perioperative Bleeding, Edema, and Ecchymosis

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

Start Date19 Mar 2024

Sponsor / Collaborator

Vanderbilt University Medical Center

100 Clinical Results associated with Epinephrine Bitartrate

100 Translational Medicine associated with Epinephrine Bitartrate

100 Patents (Medical) associated with Epinephrine Bitartrate

412

Literatures (Medical) associated with Epinephrine Bitartrate

01 Mar 2025·Journal of Neuroscience Methods

Establishing In-vivo brain microdialysis for comparing concentrations of a variety of cortical neurotransmitters in the awake rhesus macaque between different cognitive states

Article

Author: Saxena, Pankhuri ; Crayen, Max Arwed ; Treue, Stefan ; Mayer, Stella

BACKGROUNDNeuronal activity is modulated by behavior and cognitive processes. The combination of several neurotransmitter systems, acting directly or indirectly on specific populations of neurons, underlie such modulations. Most studies with non-human primates (NHPs) fail to capture this complexity, partly due to the lack of adequate methods for reliably and simultaneously measuring a broad spectrum of neurotransmitters while the animal engages in behavioral tasks.NEW METHODTo address this gap, we introduce a novel implementation of brain microdialysis (MD), employing semi-chronically implanted guides and probes in awake, behaving NHPs facilitated by removable insets within a standard recording chamber over extrastriate visual cortex (here, the visual middle temporal area (MT)). This approach allows flexible access to diverse brain regions, including areas deep within the sulcus.RESULTSReliable concentration measurements of GABA, glutamate, norepinephrine, epinephrine, dopamine, serotonin, and choline were achieved from small sample volumes (<20 µl) using ultra-performance liquid chromatography with electrospray ionization-mass spectrometry (UPLC-ESI-MS). Comparing two behavioral states - 'active' and 'inactive', we observe subtle concentration variations between the two behavioral states and a greater variability of concentrations in the active state. Additionally, we find positively and negatively correlated concentration changes for neurotransmitter pairs between the behavioral states.CONCLUSIONSTherefore, this MD setup allows insights into the neurochemical dynamics in awake primates, facilitating comprehensive investigations into the roles and the complex interplay of neurotransmitters in cognitive and behavioral functions.

01 Jan 2025·The Journal of Allergy and Clinical Immunology: In Practice

Hazelnut oral immunotherapy desensitizes hazelnut but not other tree nut allergies (Nut CRACKER Study)

Article

Author: Elizur, Arnon ; Goldberg, Michael R ; Lidholm, Jonas ; Appel, Michael Y ; Holmqvist, Marie ; Nachshon, Liat ; Koren, Yael ; Epstein-Rigbi, Naama ; Mattsson, Lars ; Levy, Michael B

BACKGROUNDData on oral immunotherapy (OIT) for hazelnut allergy is limited and its potential to cross-desensitize for other nuts is unknown.OBJECTIVETo study the efficacy and safety of hazelnut OIT in desensitizing hazelnut and additional tree nuts.METHODSA prospective observational study of 30 hazelnut allergic patients aged ≥4 years who underwent hazelnut OIT. Full desensitization (4000 mg protein) rates were compared to 14 observational controls, and immunological changes during OIT were measured. Cross-desensitization was determined in cases of walnut and cashew co-allergy (n=12). Inhibition of IgE binding to walnut by hazelnut was evaluated in a separate set of walnut-hazelnut dual allergic patients, by ELISA.RESULTSThe rate of full hazelnut desensitization following OIT was 96.7% (29/30) compared to 14.3% (2/14) in controls (OR=25.7, 95% CI 3.7-178.7, p<0.001). Five patients (16.7%) were treated with injectable epinephrine for home reactions. Hazelnut SPT and sIgE to hazelnut and its main components, Cor a 9, 14 and 16, decreased while sIgG4 increased during OIT. A maintenance dose of 1200 mg hazelnut protein was sufficient to maintain full desensitization. No cross-desensitization was noted in dual hazelnut-cashew allergic patients (n=6). In dual hazelnut-walnut allergic patients, an increase in the walnut eliciting dose was observed in 2/6 (33.2%) patients (to 1200 and 4200 mg, respectively). Similarly, by cross-inhibition ELISA, hazelnut competed for IgE-binding to walnut in 5/25 (20%) hazelnut-walnut co-allergic patients.CONCLUSIONSHazelnut OIT is highly effective, with a similar safety profile as OIT to other nuts. Cross-desensitization to walnut and cashew is unlikely.

01 Dec 2022·Revista Brasileira de Ortopedia

WALANT na osteossíntese percutânea do escafoide

Article

Author: Folberg, Celso Ricardo ; Pedrozo, Vitor Bernardes ; Alves, Jairo André de Oliveira ; Pereira, Fernando Maurente Sirena

News (Medical) associated with Epinephrine Bitartrate

13 Jun 2023

·www.globenewswire.com

Alladapt Immunotherapeutics Announces Topline Pediatric Data from Phase 1/2 Harmony Study Evaluating ADP101 for the Treatment of Patients with Mono- and Multi-Food Allergy, as Presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress

-Results from primary analysis conducted in pediatric patients demonstrate dose-dependent and clinically meaningful responses in addition to a favorable safety and tolerability profile- -Harmony, which was designed with a “low and slow” patient-centric up-dosing protocol, is the first clinical study to successfully evaluate a pharmaceutical-grade oral immunotherapy in both mono- and multi-allergen settings- -Results from Harmony support goal to progress ADP101 to Phase 3 development - MENLO PARK, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics, Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, today announced topline results from the Phase 1/2 Harmony study evaluating the efficacy and safety of ADP101 for the treatment of food allergy. The findings—which demonstrated dose-dependent, clinically meaningful responses, and a favorable safety and tolerability profile in pediatric patients with mono- and multi-food allergies—were presented in an oral session and a flash talk at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress June 9-11, 2023 in Hamburg, Germany. ADP101 is an investigational, potentially best-in-class, pharmaceutical-grade, multi-allergen oral immunotherapy (OIT) designed to simultaneously desensitize patients allergic to one or more of the most common allergenic foods including egg, milk, tree nuts, peanut, fin fish, shrimp, wheat, soy, and sesame. “We believe these encouraging topline results from our Harmony study support ADP101’s potential to be a safe and effective treatment option for children with one or more of the world’s most common food allergies,” said Ashley Dombkowski, Ph.D., Chief Executive Officer of Alladapt. “From the outset, a patient-centric approach to dosing has been vitally important to us, and as a result, our clinical team carefully designed the Harmony study to incorporate a ‘low and slow’ up-dosing protocol, with the intentional absence of an initial dose escalation day, to help minimize adverse reactions and the burden on the patient and the treating physician. Additionally, ADP101 is designed such that the pace of dosing enables physicians to customize a schedule that fits their patients’ needs—which we believe may greatly improve the overall patient experience and thus adherence. With this milestone, we are one step closer to our goal of delivering a pharmaceutical-grade, broadly applicable OIT to patients and providers. On behalf of our entire team, I am grateful for our clinical trial sites, our development partners, and the patients and families who participated in our Harmony study.” Phase 1/2 Harmony Study Pediatric Data Highlights: The study demonstrated clinically meaningful results and a dose-dependent response across multiple efficacy endpoints, with reported p-values comparing high-dose active treatment versus placebo. Desensitization to 600mg or more of protein from 1 or more qualifying allergens at 40 weeks was observed in 20.0%, 38.1% and 55.0% in those receiving placebo (pooled), low-dose ADP101 and high-dose ADP101, respectively (p=0.048, α=0.025). In a pre-specified supplemental analysis in the intent-to-treat population, taking into account COVID-19 site closures and other administrative challenges, desensitization at the 600mg level of protein was demonstrated in 21.5%, 40.5% and 58.0% of patients, respectively (p=0.013). Additionally, efficacy trends favoring high-dose ADP101 were noted across secondary efficacy endpoints: Desensitization of 1 or more foods at the 1000mg of protein or higher threshold was observed in 15.0%, 23.8% and 50.0% in placebo, low-dose ADP101 and high-dose ADP101, respectively (p=0.041).Desensitization of 2 or more foods at the 600mg of protein or higher threshold was observed in 0%, 22.2% and 55.6% of the same dose groups (p=0.006).Desensitization of 2 or more foods at the 1000mg of protein or higher threshold was observed in 0%, 11.1% and 44.4% of the same dose groups (p=0.021). The study also showed desensitization potential to multiple food allergens simultaneously, with high-dose ADP101 showing a strong response that persisted at the 1000mg or higher threshold. The multiple allergen desensitization trends were broadly observed across foods and occurred in individual patients across unrelated food groups. Secondary safety endpoints also showed that ADP101 was well-tolerated, with most treatment emergent adverse events classified as mild or moderate and occurring during the up-dosing treatment period. In the dose-maintenance phase, no adverse events were reported with a frequency >15% in any treatment group. There were no severe anaphylactic events or discontinuations for anaphylaxis attributed to ADP101. No life-threatening or fatal events occurred during the Harmony study. Epinephrine was primarily used for mild or moderate events and usage occurred with decreased frequency in the maintenance phase. There were no discontinuations following epinephrine use in the ADP101 active treatment arms. There was no evidence of treatment-associated sensitization to new allergens during the study. Commented Warner Carr, M.D., Allergy & Asthma Associates of Southern California, and a primary investigator in the Harmony study: “There is an urgent need for FDA approved food allergy interventions. Oral immunotherapy has the potential to fundamentally modify a patient’s immune system at the molecular level, which over time, could lead to meaningful and improved levels of protection from accidental exposures. In addition to its potential as a standalone OIT, if approved, I believe ADP101 could also be explored as the backbone of combination therapy with a range of immune-modulating biologics.” Added Dana McClintock, M.D., Alladapt’s Chief Medical Officer: “Based on these Harmony data, we are now looking ahead to a Phase 3 program to support regulatory approval of ADP101. Food allergy is a largely invisible, chronic disease that places a severe immunological and psychological burden on patients and their families. With limited treatment options, clinicians are actively seeking effective, practical interventions that could be broadly accessed by as many of their patients as possible. As we progress our clinical program, we intend to continue partnering with the food allergy community to ensure these needs are well reflected in our program.” Alladapt intends to submit the full Harmony study results for peer-reviewed publication and anticipates initiating the Phase 3 program focused on the pediatric population in 2024. The Harmony study also evaluated 12 adult allergy patients as an exploratory cohort. The Encore Open-Label Extension study following Harmony is currently ongoing. The data presentations may be found on EAACI’s website. About the Harmony StudyThe Phase 1/2 Harmony study is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of ADP101 for inducing desensitization in patients with single or multiple food allergies. Eligible patients had a qualifying food allergy to 1-5 foods contained in ADP101, defined as dose-limiting symptoms on exposure to ≤100mg of protein on double-blind, placebo-controlled food challenge (DBPCFC) at screening. Per protocol, the trial enrolled 61 subjects aged 4-17 in a pediatric cohort, and 12 subjects aged 18-55 in an exploratory adult cohort. Subjects were randomized 2:2:1:1 to high-dose ADP101, low-dose ADP101, high-dose placebo and low-dose placebo. About Alladapt Immunotherapeutics Alladapt Immunotherapeutics, Inc. is a private, clinical-stage biopharmaceutical company developing prescription therapeutics targeting food allergy. ADP101, the Company’s lead product candidate, is an investigational oral immunotherapy representing the nine food groups responsible for the vast majority of significant food allergic reactions globally. The Company recently completed its Harmony study, a Phase 1/2, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of ADP101 for the simultaneous treatment of one or more severe food allergies in children and adults. Encore, an open-label extension study of the Harmony study, is currently ongoing. Alladapt was co-founded in 2018 by biotechnology entrepreneur, Ashley Dombkowski, Ph.D. and allergist, clinician and protein biochemist, Kari Nadeau, M.D., Ph.D. Dr. Nadeau currently serves as the Chair of the Department of Environmental Health at Harvard School of Public Health and John Rock Professor of Climate and Population Studies. Food allergen specific OIT conducted by Dr. Nadeau and other food allergy experts is an approach that has shown consistent promising results through administration of increasing amounts of an allergen to individuals with food allergy to raise their reactive threshold and decrease the severity of allergic responses to the allergenic food. This work, combined with research on disease mechanisms, pathways, and protein structures, led the founders to envision biopharmaceutical interventions capable of addressing food allergy due to a wide-ranging set of foods. For more information, please visit the Company's website at www.alladapt.com. Investor Contact: William WindhamSolebury Strategic Communications 646-378-2946wwindham@soleburystrat.com Media Contact: Amy BonannoSolebury Strategic Communications 914-450-0349abonanno@soleburystrat.com

Clinical ResultImmunotherapyPhase 3

24 Oct 2022

·www.biospace.com

ARS Pharmaceuticals Announces FDA Acceptance of NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis

SAN DIEGO--(BUSINESS WIRE)-- ARS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review ARS’ New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date that is anticipated in mid-2023. “The FDA acceptance of our NDA for neffy is a major milestone in our efforts to bring to patients the ability to deliver epinephrine with comparable pharmacokinetics to an intramuscular injection, but in a needle-free and simple to administer nasal spray,” said Richard Lowenthal, President and CEO of ARS Pharmaceuticals. “We appreciate that the FDA recognizes the potential clinical benefit of this novel approach to treating patients with severe allergies and look forward to working with the FDA during this process, with the goal of potentially changing the treatment paradigm for the millions of patients with or at-risk for severe allergic reactions (type I).” The NDA submission to the FDA was based on data from four primary registration studies supporting that a 2 mg intranasal dose of neffy met all clinical endpoints recommended by regulators and that its pharmacokinetics were within the range of approved epinephrine injection products. These data included studies in adults, with self-administration and caregiver administration, as well as in children with Type I allergies ≥30 kg (66 lbs). In addition, neffy has been well-tolerated to date with more than 500 individuals receiving at least one dose, and many with repeat administration. The majority of adverse events in clinical trials were mild in nature without any meaningful nasal irritation or pain. About Allergic Reactions (Type I) including Anaphylaxis Type I severe allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 25 to 40 million people in the United States who experience Type I severe allergic reactions. Of those, only 3.3 million currently have an active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency. About ARS Pharmaceuticals, Inc. ARS Pharmaceuticals is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy® (previously referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit .

09 Jun 2022

·www.globenewswire.com

Aquestive Therapeutics, Inc. Announces Closing of $8.5 Million Registered Direct Offering

WARREN, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor and certain of the Company’s executives, to purchase 8,850,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,850,000 shares of common stock at a purchase price per share (and accompanying warrant) of $0.96 for the institutional investor and $1.09 for the Company’s executives for gross proceeds of approximately $8.5 million. The warrants have a five-year term, are exercisable six months following the date of issuance and have an exercise price of $0.96 per share. “We are pleased to welcome a new and significant shareholder to the Company,” stated Daniel Barber, President and CEO of Aquestive Therapeutics. “Given the current market environment, we will continue to focus on cash generation through a variety of methods. These include attaining and maximizing profitability in our commercial and manufacturing groups, tightly managing corporate expenses, and continuing our licensing activities. We remain focused on the FDA’s review of Libervant and the ongoing clinical development of our oral epinephrine oral film candidate, AQST-109. Our strategies are designed to ensure that we continue to have the resources necessary to rapidly progress both of our key pipeline programs.” A.G.P./Alliance Global Partners acted as the sole placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as a financial advisor for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-254775) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A final prospectus supplement describing the terms of the proposed offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Aquestive Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. For more information, visit Aquestive.com and follow us on LinkedIn. PharmFilm®, Sympazan® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. Investor Inquiries: ICR Westwicke Stephanie Carrington stephanie.carrington@westwicke.com 646-277-1282

FinancingCollaborate

100 Deals associated with Epinephrine Bitartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02149	Epinephrine Bitartrate	C01CA24 B02BC09 S01EA01 R03AA01 A01AD01 R01AA14	DB00668

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypotension	US	International Medication Systems Ltd.	15 Aug 2022
Shock, Septic	US	International Medication Systems Ltd.	15 Aug 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypotension	IND Application	CN	Grand Pharmaceutical (China) Co., Ltd.	05 Jul 2022
Hypotension	IND Application	CN	ALK-Abello A/S	05 Jul 2022
Bronchial Spasm	Discovery	US	Amphastar Pharmaceuticals, Inc.	01 Aug 2010
Dyspnea	Discovery	US	Amphastar Pharmaceuticals, Inc.	01 Aug 2010
Asthma	Discovery	US	Bausch & Lomb (Australia) Pty Ltd.	09 Mar 1956

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AQ109301 (ACAAI2024)	Not Applicable	First line	-	Sublingual Epinephrine Film (DESF)	(xmnefijknj) = comparable to EAIs or IM injection uuwzwpksvm (emooutvcmt ) View more	Positive	24 Oct 2024
				Epinephrine Autoinjectors (EAI)
NCT03860974 (CTgov)	Phase 4	-	100	epinephrine+ropivacaine (Serratus Plane (Single Injection))	hxtvzcyfaw(vawacsvxbw) = nwlkhtmmve aqwelzhqww (qeafzkajth, otmxceticl - ygobuxkowd) View more	-	21 Sep 2022
				Paravertebral block (single injection) (Paravertebral (Single Injection))	hxtvzcyfaw(vawacsvxbw) = aqdwzrhrmj aqwelzhqww (qeafzkajth, yvimvamkcf - ikmnfsamzx) View more
NCT04688346 (CTgov)	Phase 2/3	Drug-Related Side Effects and Adverse Reactions	13	HemeRX epinephrine pellets (Control)	hniququhvb(qitkmmqctq) = brunamuyea guktbrrefd (ianiairkru, aylqbdaxql - cqdsrqjfwz) View more	-	13 May 2021
				HemeRX epinephrine pellets (Intervention)	hniququhvb(qitkmmqctq) = vjuonhztuc guktbrrefd (ianiairkru, pbqjjvgzso - gueeorheit) View more
NCT01602692 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Pain, Postoperative	40	Tumescent Solution with dilute epinephrine (Tumescent Solution With Dilute Epinephrine)	fbyqdbzdvh(yqqbygjxqd) = rscdsjrxmw fkrybvwjrm (cvdqyfuhcc, xjepaypwge - tvtkdkcvfo) View more	-	05 Oct 2020
				Tumescent solution with dilute lidocaine and epinephrine (Tumescent Solution With Dilute Lidocaine and Epinephrine)	fbyqdbzdvh(yqqbygjxqd) = zhcaumwyos fkrybvwjrm (cvdqyfuhcc, rrezsesvsb - qqgesjmmkm) View more
NCT02280291 (CTgov)	Phase 4	Pain \| Fractures, Bone	100	epinephrine+lidocaine+bupivacaine (Ankle Single Shot Block (SSB))	xbbdgujrmr(oxedgiqaxr) = owvkqeaqdd bhaqjyfuak (qcubldbxlr, trtrtgtwnk - etcqyaiydr) View more	-	30 Mar 2020
				epinephrine+lidocaine+bupivacaine (Ankle OnQ (Continuos Sedation OnQ Pump))	xbbdgujrmr(oxedgiqaxr) = qwgombicnr bhaqjyfuak (qcubldbxlr, yrpyepqugb - bkppfocyor) View more
NCT00624650 (HEAL, CTgov)	Phase 2	Acute Lung Injury	33	Epinephrine+Fluid Bolus (crystalloid or albumin)+Norepinephrine+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (Modified FACTT (Control))	bjtghdypdp(vgauionaby) = edqdblmfhi tagugdblkp (qbbjemctib, ajnovcjzty - gpvibisuyj) View more	-	10 Sep 2019
				Epinephrine+Fluid Bolus (crystalloid or albumin)+Norepinephrine+Phenylephrine+Diuresis (furosemide) part I+Dobutamine+Vasopressin (EVLW)	bjtghdypdp(vgauionaby) = ormulcaadc tagugdblkp (qbbjemctib, hiubequxxc - ooahqqsear) View more
NCT02104414 (CTgov)	Phase 4	Hemorrhoids	11	Exparel (Exparel)	etcqahyzjn(zyzlmkauth) = uautqxabkv vyerssaoqi (yiyrxdgomc, guqohqgcvn - rgmwredalu) View more	-	04 Dec 2018
				Epinephrine+Bupivacaine HCl (Bupivacaine HCl With Epinephrine)	etcqahyzjn(zyzlmkauth) = yvdrjcwvaw vyerssaoqi (yiyrxdgomc, exwoqwdbks - piytjutqlf) View more
NCT03087604 (CTgov)	Phase 4	Anesthesia	100	Epinephrine+Thoracic epidural block+Lidocaine (Traditional Technique Group)	xddzsqcbic(gstntobikm) = ujzkhbwufq lszywwndgn (ttczdfgagv, oolzsvedyg - kqjezjqies) View more	-	23 Nov 2018
				Epinephrine+Electrical Nerve stimulation+Lidocaine (Electric Stimulation Group)	xddzsqcbic(gstntobikm) = adefbbfxvf lszywwndgn (ttczdfgagv, bgavpsbtpj - avevhezaxk) View more
NCT02379221 (CTgov)	Not Applicable	Anesthesia	49	Topical+epinephrine+benzocaine+lidocaine	ptlldtyukj(kxenodtamw) = pvpxndgrkl hwmlxttwus (djexloqiuk, hogfohcgpw - hgjroyluxh) View more	-	24 Oct 2018
NCT02619409 (CTgov)	Not Applicable	Osteoarthritis, Hip \| Arthropathy of knee joint	30	Bupivacaine Only (Bupivacaine Only)	rmeddauidk(zzxfyfgwvn) = yqeqczprer efdfgntlvt (uwjsrbykvw, svvnyfbwda - jkmggpfhuj) View more	-	17 Jul 2018
				epinephrine+bupivacaine (EPI25 Group)	rmeddauidk(zzxfyfgwvn) = ewxlvrlzfq efdfgntlvt (uwjsrbykvw, gubxvmqicc - chmzycmcqn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis